Cargando…

Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis

OBJECTIVES: This network meta-analysis aimed to assess the safety profiles of seven commonly used oral antimuscarinic drugs (darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, and tolterodine) in patients with overactive bladder (OAB). METHODS: PubMed, Cochrane Library, E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Nannan, Wu, Qiaoyan, Xu, Faren, Zhang, Xiaopeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442499/ https://www.ncbi.nlm.nih.gov/pubmed/34510960 http://dx.doi.org/10.1177/03000605211042994

Ejemplares similares

A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages
por: Gu, Hui-Yun, et al.
Publicado: (2017)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome
por: Xia, Liping, et al.
Publicado: (2021)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
por: Kosilov, Kirill Vladimirovich, et al.
Publicado: (2017)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
por: Sun, Jinping, et al.
Publicado: (2017)

Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis
por: Wang, Zijie, et al.
Publicado: (2017)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Efficacy and safety of early oral feeding in postoperative patients with upper gastrointestinal tumor: A systematic review and meta-analysis
por: Hao, Tao, et al.
Publicado: (2021)

Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis
por: Lee, Hyo-Young, et al.
Publicado: (2019)

Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis
por: Lin, Chu, et al.
Publicado: (2023)

Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis
por: He, Xiao-Yuan, et al.
Publicado: (2023)

Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study
por: Arana, Alejandro, et al.
Publicado: (2018)

Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis
por: Ma, Yan, et al.
Publicado: (2017)

Comparison of clinical efficacy and safety between dexmedetomidine and propofol among patients undergoing gastrointestinal endoscopy: a meta-analysis
por: Liu, Weihua, et al.
Publicado: (2021)

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis
por: Liu, Duanrui, et al.
Publicado: (2017)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis
por: Cui, Xiangrong, et al.
Publicado: (2017)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
por: Arlandis-Guzman, Salvador, et al.
Publicado: (2011)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
por: Liu, Hsin-Tzu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eq9fkvibdm89sqq1mj7ath7okp